bluuebunny/crossref_metadata_2025_split huggingface dataset:
The VB‐1 catheter: An improved catheter for difficult‐to‐engage internal mammary artery grafts
Authors: Warner John J. , Gehrig Thomas R. , Behar Victor S. 
Published: June 2003

AbstractAs patients with prior coronary artery bypass grafting age, internal mammary artery grafts are more frequently encountered in the cardiac catheterization laboratory. Angiography and interventions involving these grafts are often difficult, particularly in patients with tortuous subclavian anatomy and/or proximal internal mammary artery origins. We describe a new catheter shape, the Cordis Behar Internal Mammary, VB‐1, which allows selective intubations of both right and left internal mammary arteries that are not possible with conventional catheters. Cathet Cardiovasc Intervent 2003;59:361–365. © 2003 Wiley‐Liss, Inc.
Retrograde dilatation of a totally occluded ostial left anterior descending artery from saphenous venous graft in the descending aorta following stenting of the aorto‐ostial graft restenosis in a patient with left main coronary artery stenosis
Authors: Cheng Nye‐Jan , Chang Chi‐Jen , Ho Wan‐Jing 
Published: June 2003

AbstractTreatment of native coronary and saphenous vein graft aorto‐ostial stenoses with balloon angioplasty is associated with lower procedural success rates and more complications compared with percutaneous transluminal coronary angioplasty of nonostial stenoses. A patient with totally occluded ostial left anterior descending artery at ostium following aortocoronary bypass developed ostial stenosis at the saphenous vein graft in the descending aorta. The aorto‐ostial lesion of saphenous vein graft was successfully stented and was followed by retrograde dilatation of the left anterior descending artery, and the totally occluded ostial lesion was reopened. The ischemia was eliminated following the procedure. Cathet Cardiovasc Intervent 2003;59:357–360. © 2003 Wiley‐Liss, Inc.
Percutaneous coronary intervention‐associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine
Authors: Lindsay Joseph , Apple Sue , Pinnow Ellen E. , Gevorkian Natalie , Gruberg Luis , Satler Lowell F. , Pichard Augusto D. , Kent Kenneth M. , Suddath William , Waksman Ron 
Published: June 2003

AbstractIn patients with chronic renal insufficiency, further decline in renal function (DRF) after percutaneous coronary intervention (PCI) is accompanied not only by adverse in‐hospital events but also by increased risk of mortality and myocardial infarction at 1 year. This analysis was undertaken to determine if patients with normal renal function who develop DRF after PCI have a comparable increase in risk of death and myocardial infarction at 1 year, and whether this risk is independent of in‐hospital complications (death, myocardial infarction, urgent coronary artery bypass grafting). We performed a retrospective analysis of all patients from a single center who underwent successful PCI with no major in‐hospital complications who had pre‐PCI serum creatinine (SCr) ≤ 1.2 mg/dl and no history of renal insufficiency. One‐year follow‐up was obtained by mail or telephone. There were 5,967 consecutive patients who met the inclusion criteria. Of these, 208 (3.5%) developed DRF (an increase in SCr ≥ 50% of baseline). They were more likely to be older, female, non‐Caucasian, diabetic and/or hypertensive. They reported more prior cerebral or peripheral vascular events. They had undergone more complex PCI and were exposed to more radiographic contrast than the 96.5% who did not develop DRF. After adjustment for baseline variables, DRF remained an independent predictor of 1‐year mortality, myocardial infarction, and target vessel revascularization. In patients without prior renal impairment, DRF post‐PCI is rare but is associated with an increased risk of late adverse cardiac events similar to that in chronic renal insufficiency patients. Cathet Cardiovasc Intervent 2003;59:338–343. © 2003 Wiley‐Liss, Inc.
Transcatheter closure of aortopulmonary window using Amplatzer device
Authors: Naik Guruprasad D. , Chandra V. Subash , Shenoy Anand , Isaac B.C. , Shetty G.G. , Padmakumar P. , Jayranganath M. 
Published: June 2003

AbstractTwo cases of transcatheter closure of aortopulmonary window (APW) using an Amplatzer duct occluder in one and a septal occluder device in the second are described. Transcatheter device closure of APW should be considered when anatomy is favorable in terms of location and size of the defect with absence of associated anomalies. Cathet Cardiovasc Intervent 2003;59:402–405. © 2003 Wiley‐Liss, Inc.
Obstinate thrombosis during percutaneous coronary intervention in a case with heparin‐induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy
Authors: Sakai Katsuyuki , Oda Hirotaka , Honsako Akihiro , Takahashi Kazuyoshi , Miida Tutomu , Higuma Norio 
Published: June 2003

AbstractWe describe a case of massive coronary thrombus after the coronary stenting due to heparin‐induced thrombocytopenia with thrombosis syndrome (HITTS). Only argatroban was able to resolve the thrombus. This is the first case in which argatroban successfully treated massive thrombus during percutaneous coronary intervention in a patient with HITTS. Cathet Cardiovasc Intervent 2003;59:351–354. © 2003 Wiley‐Liss, Inc.
Impact of intravascular ultrasound‐guided stenting on long‐term clinical outcome: A meta‐analysis of available studies comparing intravascular ultrasound‐guided and angiographically guided stenting
Authors: Casella Gianni , Klauss Volker , Ottani Filippo , Siebert Uwe , Sangiorgio Pietro , Bracchetti Daniele 
Published: June 2003

AbstractTo date, only a few studies have compared the clinical efficacy of intracoronary ultrasound (IVUS)‐guided to angiographically guided stenting. Furthermore, it is not yet known whether the lower restenosis rate shown with the former strategy would translate into a substantial clinical advantage. Therefore, the aim of the present investigation was to improve the level of evidence of these studies by means of a formal meta‐analysis. Nine studies were considered suitable for analysis. Odds ratios (ORs) were calculated for 6‐month clinical follow‐up. Primary endpoint was a composite of death and nonfatal myocardial infarction (MI), as considered in every single study. Secondary endpoints were major adverse cardiac events (MACEs), according to single study definition, the individual cardiac events, as well as several pre‐ and postprocedure and follow‐up angiographic parameters. Overall, 2,972 patients were included. At 6 months, the OR for death and nonfatal MI was 1.13 (95% CI = 0.79–1.61; P = 0.5) for patients with IVUS‐guided stenting. However, patients with IVUS‐guided stenting had less target vessel revascularizations (OR = 0.62; 95% CI = 0.49–0.78; P = 0.00003) and MACEs (OR = 0.79; 95% CI = 0.64–0.98; P = 0.03) compared to angiographically guided stenting. In addition, subjects treated with IVUS‐guided stenting had significantly less binary restenosis (OR = 0.75; 95% CI = 0.60–0.94; P = 0.01). The present meta‐analysis demonstrates that IVUS‐guided stenting implantation has a neutral effect on long‐term death and nonfatal MI compared to an angiographic optimization. However, IVUS‐guided stenting significantly lowers 6‐month angiographic restenosis and target vessel revascularizations. Whether these benefits could be very helpful when dealing with lesions at high risk for restenosis is still an issue. Cathet Cardiovasc Intervent 2003;59:314–321. © 2003 Wiley‐Liss, Inc.
Staged rehabilitation of ductal origin of the left pulmonary artery in an infant fallot's tetralogy
Authors: Peirone Alejandro , Lee Kyong‐Jin , Yoo Shi‐Joon , Musewe Norman , Smallhorn Jeffrey , Benson Lee 
Published: June 2003

AbstractIsolation of a branch pulmonary artery from ductal closure is an unusual finding in patients with tetralogy of Fallot. A case report of a newborn is presented where the closing arterial duct was balloon‐dilated and stented to reestablish blood supply to the affected lung as a strategy of improving systemic saturations and promoting the growth of the hiliar branch pulmonary artery. Five months after the initial palliation, complete surgical repair with stent removal was successfully achieved. Cathet Cardiovasc Intervent 2003;59:392–395. © 2003 Wiley‐Liss, Inc.
Acute coronary syndrome secondary to a complex lesion within a stent implanted over 6 years previously
Authors: Baker David M. , Osborn Larry A. 
Published: June 2003

AbstractWe report on an acute coronary syndrome resulting from a complex severe lesion within a stent over 6 years after implantation. This may represent an uncommon long‐term limitation of coronary artery stenting. Cathet Cardiovasc Intervent 2003;59:366–368. © 2003 Wiley‐Liss, Inc.
Large left atrial thrombus formation despite warfarin therapy after device closure of a patent foramen ovale
Authors: Cetta Frank , Arruda M. Janine , Graham Lynn C. 
Published: June 2003

AbstractAppropriate anticoagulation after transcatheter device placement is controversial. Patients with no history of thromboembolism or neurologic event typically receive antiplatelet therapy for several months while the device endothelializes. For patients with a history of stroke, there are no established guidelines for postdevice anticoagulation. Most patients receive warfarin, antiplatelet therapy, or a combination. Thrombus formation after transcatheter device placement has been reported for most commercially available devices. We describe a patient who developed a left atrial thrombus after closure of a patent foramen ovale with a CardioSEAL device. The patient had a normal hypercoaguable laboratory evaluation prior to device placement. Thrombosis occurred despite warfarin therapy before and after device placement. The patient's international normalized ratio was checked every 2 weeks after device placement and ranged between 2.0 and 2.8. She had no clinical arrhythmia during this time period. The left atrial thrombus was detected on routine follow‐up transthoracic echocardiogram performed 6 months after device deployment. A subsequent transesophageal echocardiogram demonstrated no residual shunt, appropriate positioning of the device, flat against the septum, and a 1 × 2 cm thrombus attached to the superior and posterior left atrial arm near the junction with the native septum. A fluoroscopic image demonstrated no arm fractures. The device and thrombus were subsequently removed at surgery without complication. This case is perplexing in that the patient received appropriate anticoagulation had a negative hypercoaguable work‐up, no residual shunt, and a well‐positioned device. Cathet Cardiovasc Intervent 2003;59:396–398. © 2003 Wiley‐Liss, Inc.
Stent deployment failure: Reasons, implications, and short‐ and long‐term outcomes
Authors: Nikolsky Evgenia , Gruberg Luis , Pechersky Sirush , Kapeliovich Michael , Grenadier Ehud , Amikam Shlomo , Boulos Monther , Suleiman Mahmoud , Markiewicz Walter , Beyar Rafael 
Published: June 2003

AbstractStents have revolutionized percutaneous coronary interventions (PCI), impacting on both acute and long‐term results. However, despite improvements in stent design, stent deployment failure is not an unusual event. The aim of the present study was to assess the frequency and causes of stent deployment failure, as well as the outcome of these patients. Between 1997 and 2001, a total of 3,537 patients underwent stent‐assisted PCI and delivery of 5,275 stents was attempted. In the majority of patients (118; 78.1%), stenting was performed as provisional; in the remaining 33 (21.8%) as a bailout procedure. A total of 175 (3.3%) stents in 151 (4.3%) patients failed. Failure to deliver the stent to the lesion site was the main cause in 139 patients (92%) and failure either to expand adequately the stent or premature disengagement of the stent from the balloon in only 12 patients (8%). Peripheral stent embolization occurred in 10 (0.3%) patients. Deployment of a different stent in place of the failed one was attempted in 122 patients and was successful in the majority (108; 88.5%). In‐hospital major adverse cardiac events were observed in six patients (4%): three patients required emergency coronary artery bypass surgery, two had a myocardial infarction (MI), and one patient underwent urgent repeat coronary intervention. At a mean follow‐up of 32.2 ± 17.7 months, 22 major adverse cardiac event occurred in 17 patients (11.2%): 1 cardiac death, 3 patients had an MI, and 18 patients required target vessel revascularization. One‐year event‐free survival for the whole group was 91.2%. Patients with stent embolization did not have any major adverse cardiac or vascular events. Thus, the rate of stent deployment failure in our series was 3.3%, mainly due to failure to deliver the stent to the site. Another stent was successfully deployed in the majority of cases and these patients had favorable short‐ and long‐term outcomes. Cathet Cardiovasc Intervent 2003;59:324–328. © 2003 Wiley‐Liss, Inc.
Improvement of protein‐losing enteropathy by coil embolization of the left azygos vein
Authors: Ishii Akira , Fuse Shigeto , Kubo Noriaki , Hatakeyama Kinya , Takamuro Motoki , Tomita Hideshi , Tsutsumi Hiroyuki 
Published: June 2003

AbstractWe report a 17‐year‐old boy with double‐outlet right ventricle, atrioventricular septal defect, pulmonary stenosis, and persistent left superior vena cava who developed a protein‐losing enteropathy, which was cured by coil embolization of the left azygos vein, thereby interrupting the vein‐to‐vein shunt. Cathet Cardiovasc Intervent 2003;59:399–401. © 2003 Wiley‐Liss, Inc.
Use of a percutaneous vascular suture device for closure of an inadvertent subclavian artery puncture
Authors: Fraizer Michael C. , Chu William W. , Gudjonsson Thorbjorn , Wolff Matthew R. 
Published: June 2003

AbstractA well‐known complication of central venous catheterization is inadvertent arterial sheath placement. Sheath removal from noncompressible arteries has the potential for severe complications. We report a case of inadvertent subclavian arterial sheath placement during an attempted internal jugular venous catheterization. This was successfully removed using a percutaneous vascular suture device. Cathet Cardiovasc Intervent 2003;59:369–371. © 2003 Wiley‐Liss, Inc.
Endovascular stent implantation in patients with stenotic aortoarteriopathies: Early and medium–term results
Authors: Siwik Ernest S. , Perry Stanton B. , Lock James E. 
Published: June 2003

AbstractData regarding stent implantation for stenotic aortoarteriopathy (SAA) are incomplete. We report on nine patients with this rare syndrome who underwent arterial stent implantation. Indications, results, and complications for patients with SAA were reviewed. Nine patients underwent 11 procedures. Twenty‐two stents were implanted in the aorta or brachiocephalic vessels. Five patients had diffuse stenoses, three patients had middle aortic syndrome, and one patient had thoracic and abdominal coarctation. Associated diagnoses included Williams syndrome (2), neurofibromatosis (2), Takayasu's (1), and congenital rubella (1). Median gradient was 60 mm Hg (20–140 mm Hg). Poststent gradient was 15 mm Hg (0–60 mm Hg; P < 0.001). Additional stents were implanted in two patients and five underwent stent redilation. Two patients (22%) were found to have aneurysm formation. Stent implantation effectively provides gradient relief in SAA. Gradient reduction persists or is amenable to redilation. Importantly, however, uncomplicated stent implantation does not preclude aneurysm formation and may be more common than in traditional patient groups. Cathet Cardiovasc Intervent 2003;59:380–386. © 2003 Wiley‐Liss, Inc.
The Genesis stent: A new low‐profile stent for use in infants, children, and adults with congenital heart disease
Authors: Forbes Thomas J. , Rodriguez‐Cruz Edwin , Amin Zahid , Benson Lee N. , Fagan Thomas E. , Hellenbrand William E. , Latson Larry A. , Moore Phillip , Mullins Charles E. , Vincent Julie A. 
Published: June 2003

AbstractPlacement of intravascular stents that can reach adult size in infants and smaller children has been limited by the large profile and poor flexibility of currently available stents. In vitro and in vivo testing of the Genesis stent was performed to evaluate crimpability, predeployment flexibility, and radial strength. Comparisons were made to the Palmaz iliac and IntraStent (IS) LD stents. Nine physicians placed 30 Genesis stents in swine pulmonary and systemic arteries to evaluate stent deliverability/crimpability. Two swine were recovered and underwent a second catheterization 8 weeks later, where the stents (n = 8) were reexpanded to maximal size. Angiographic and intravascular ultrasound (IVUS) assessments were performed. In vitro testing revealed the Genesis stent to have superior crimpability, flexibility, and comparable radial strength to the Palmaz iliac stent, and superior crimpability and radial strength and comparable flexibility to the IS LD series. During in vivo testing, the physicians graded the Genesis stent superior to the Palmaz stent regarding crimpability and deliverability, and superior to the IS LD stent in regard to crimpability, and comparable to or superior in deliverability. In the chronic animals, the Genesis stent was expanded up to maximal diameter 8 weeks following implantation. Angiographic and IVUS revealed no fractures no in‐stent restenosis. The Genesis stent can be easily delivered through smaller sheaths, which will facilitate their use in infants and smaller children with vascular stenosis. Cathet Cardiovasc Intervent 2003;59:406–414. © 2003 Wiley‐Liss, Inc.
Transcatheter interventions across an inferior vena cava filter
Authors: Rhodes John F. , Miller Stephen G. , Lane Geoffrey K. , Latson Larry A. 
Published: June 2003

AbstractPatients who suffer from an embolic event often undergo placement of an inferior vena caval filter. Few data are available regarding treatment of this patient population with concurrent right‐to‐left shunting across an atrial communication. We report four cases of transcatheter device closure of an atrial communication across an inferior vena cava filter. Cathet Cardiovasc Intervent 2003;59:333–337. © 2003 Wiley‐Liss, Inc.
Successful rotational atherectomy in the setting of extensive coronary dissection: A case of failed balloon angioplasty in a nondilatable calcified lesion complicated by balloon rupture and extensive dissection
Authors: Pedersen Wesley R. , Goldenberg Irvin F. , Johnson Randall K. , Mooney Michael R. 
Published: June 2003

AbstractWe describe a case of rotational atherectomy (RA) used in the setting of extensive coronary dissection. Unsuccessful predilitation of a heavily calcified proximal LAD stenosis resulted in balloon rupture, which produced occlusive dissection extending into the mid LAD. Limited options for this patient required that we perform RA to permit stent delivery and deployment and avoid anterior myocardial infarction. A brief discussion of reasons for balloon angioplasty failure and the potential role for subsequent RA is given. Predictors for coronary perforation when performing RA are reviewed. Our rationale and strategy to avoid the increased risk of perforation with RA in this contraindicated setting of extensive dissection is given. Cathet Cardiovasc Intervent 2003;59:329–332. © 2003 Wiley‐Liss, Inc.
Upendra Kaul, Ripen K. Gupta, Kottaram K. Haridas, Saligrama S. Ramesh, Kamal K. Sethi, Balbir Singh, Rajiv Agarwal, Ram D. Yadave, Tapan Ghose, Rakesh R. Sapra, Rajiv Bajaj, Madhukar Shahi, Ajit Bhagwat, Pramod Kumar, Omen P. Mathews, Pratik K. Soni. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: A 30‐day follow‐up study. Cathet Cardiovasc Intervent 2002;57(4):497–503
Authors: Kaul Upendra 
Published: June 2003

AbstractThe original article to which this Erratum refers was published in Cathet Cardiovasc Intervent (2002)57:497–503
Organization of postsynaptic density proteins and glutamate receptors in axodendritic and dendrodendritic synapses of the rat olfactory bulb
Authors: Sassoé‐Pognetto Marco , Utvik Jo K. , Camoletto Paola , Watanabe Masahiko , Stephenson F. Anne , Bredt David S. , Ottersen Ole P. 
Published: June 2003

AbstractGlutamate neurotransmission in the olfactory bulb involves both axodendritic synapses and dendrodendritic reciprocal synapses and possibly also extrasynaptic receptors. By using a sensitive immunogold procedure, we have investigated the organization of two synaptic scaffolding molecules, PSD‐95 and PSD‐93, as well as N‐methyl‐D‐aspartate (NMDA) and α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐proprionic acid (AMPA) receptors, at these heterogeneous glutamate signaling sites. Immunolabeling for PSD‐95 and PSD‐93 was present in all major types of putative glutamatergic synapse, suggesting that these proteins are essential components of the synaptic signaling apparatus. The linear density and the subsynaptic distribution of PSD‐95/PSD‐93 gold particles did not differ significantly between axodendritic and dendrodendritic synapses. Antibodies recognizing NMDA and AMPA receptor subunits also labeled asymmetric synapses throughout the olfactory bulb. Immunolabeling for the AMPA receptor subunits GluR2/3 was similar in all types of synapse. In contrast, immunogold signals for the NR1 subunit of NMDA receptors varied significantly among different synapse populations, with olfactory nerve synapses in the glomerular layer showing the lowest labeling intensity. Although the lateral dendrites of mitral and tufted cells have been reported to respond to glutamate, they did not display significant plasma membrane labeling for the NR1 subunit or for PSD‐95, suggesting that the physiological effects of glutamate at these sites are mediated by NMDA autoreceptors that are not clustered and occur only at a low density on the dendritic surface. Our quantitative analysis of olfactory bulb synapses indicates that the density of NMDA receptors is not determined by the complement of PSD‐95/PSD‐93. The latter molecules appear to be expressed in an all‐or‐none fashion and may form a standard lattice common to different types of glutamatergic synapse. J. Comp. Neurol. 463:237–248, 2003. © 2003 Wiley‐Liss, Inc.